Medical release archive

CARBON studies showed uncontrolled asthma is associated with an increased carbon footprint of asthma care

New Fasenra data from the PONENTE trial show sustained, robust oral corticosteroid reductions in largest ever steroid-sparing trial in severe asthma

New tezepelumab data show 86% reduction in exacerbations in patients with severe asthma and comorbid nasal polyps

New data at ESC Congress 2021 showcase AstraZeneca’s leading cardiovascular, renal and metabolic portfolio

Bydureon BCise (exenatide extended-release) approved in the US for the treatment of type-2 diabetes in paediatric patients ages 10 years and older

AstraZeneca’s investigational MPO inhibitor AZD4831 shows promise in patients with heart failure and a preserved ejection fraction

New data at Heart Failure 2021 showcases AstraZeneca’s leading and diverse heart failure portfolio

New Fasenra data from the MELTEMI extension trial confirm long-term safety and efficacy in severe eosinophilic asthma for up to five years

New tezepelumab data continue to strengthen profile for a broad population of severe asthma patients

First patients dosed in three dermatology trials evaluating Fasenra in bullous pemphigoid, atopic dermatitis and chronic spontaneous urticaria